EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 November 2021
EMA/CHMP/371445/2021
Committee for Medicinal Products for Human Use (CHMP)

Ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance

Draft Agreed by Pharmacokinetics Working Party (PKWP)	28 October 2020
Adopted by CHMP for release for consultation	11 November 2021
Start of public consultation	16 December 2021
End of consultation (deadline for comments)	31 March 2022
Agreed by Pharmacokinetics Working Party	
Adopted by CHMP	
Date for coming into effect	

Comments should be provided using this template. The completed comments form should be sent to PKWPsecretariat@ema.europa.eu

Keywords	***Bioequivalence, generics, ibrutinib***

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (PKWP)*

BCS Classification	**BCS Class:** ☐ **I** ☐ **III** ☒ **Neither of the two** **Background:** Ibrutinib may be considered a low solubility compound with complete absorption.
Bioequivalence study design *in case a BCS biowaiver is not feasible or applied*	**single dose** **cross-over**
	healthy volunteers
	☒ **fasting** ☐ **fed** ☐ **both** ☐ **either fasting or fed**
	Strength: 140 mg for the capsules and 560 mg for the tablets **Background:** Highest strength to be used for a drug with linear pharmacokinetics and low solubility.
	Number of studies: One single dose study for each dosage form.
Analyte	☒ **parent** ☐ **metabolite** ☐ **both**

	☒ **plasma/serum** ☐ **blood** ☐ **urine**
	Enantioselective analytical method: ☐ **yes** ☒ **no**
Bioequivalence assessment	**Main pharmacokinetic variables:** AUC_{0-t} and C_{max}
	90% confidence interval: 80.00–125.00%

20 * Since high intra-subject variability (CV_{intra} > 30%) is expected, the applicants might follow respective guideline recommendations.